Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spevatamig + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Phanes Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Spevatamig + gemcitabine + nab-paclitaxel** is a combination regimen currently under investigation for advanced and metastatic cancers, especially pancreatic ductal adenocarcinoma, gastric, gastroesophageal junction, and biliary tract carcinomas. Spevatamig (PT886) is a native IgG-like bispecific monoclonal antibody developed by Phanes Therapeutics that targets both claudin 18.2 and CD47, designed to block tumor immune evasion and enhance cytotoxicity. Gemcitabine is a nucleoside analog chemotherapy (antimetabolite) disrupting DNA synthesis. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a solvent-free formulation of paclitaxel, a microtubule inhibitor that disrupts mitosis and induces apoptosis in dividing cancer cells. The combination is administered intravenously and is being evaluated in a multi-cohort Phase 1/2 trial (TWINPEAK) for safety, tolerability, and clinical activity.
- Other names
- spevatamig + gemcitabine + nab-paclitaxel
02
Targets
Claudin 18.2CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on spevatamig + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spevatamig + gemcitabine + nab-paclitaxel.